

Mirco Pistelli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6840559/publications.pdf>

Version: 2024-02-01

32
papers

605
citations

623188

14
h-index

610482

24
g-index

32
all docs

32
docs citations

32
times ranked

1326
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic Impact of Ki-67 Change in Locally Advanced and Early Breast Cancer after Neoadjuvant Chemotherapy: A Single Institution Experience. <i>Journal of Oncology</i> , 2021, 2021, 1-7.	0.6	10
2	The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial. <i>Scientific Reports</i> , 2021, 11, 13770.	1.6	8
3	The Impact of Lifestyle Interventions in High-Risk Early Breast Cancer Patients: A Modeling Approach from a Single Institution Experience. <i>Cancers</i> , 2021, 13, 5539.	1.7	7
4	Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients. <i>Clinical Breast Cancer</i> , 2020, 20, e89-e98.	1.1	8
5	Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting. <i>International Journal of Cancer</i> , 2020, 146, 1917-1929.	2.3	4
6	EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 83.	2.2	6
7	Irinotecan-Induced Transient Dysarthria: Case Series and Updated Literature Review. <i>Oncology and Therapy</i> , 2020, 8, 147-160.	1.0	2
8	Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence. <i>Journal of Cellular Physiology</i> , 2020, 235, 7900-7910.	2.0	19
9	Healthcare cost of HER2-positive and negative breast tumors in the United States (2012-2035). <i>Cancer Treatment Reviews</i> , 2017, 60, 12-17.	3.4	15
10	Hyponatremia normalization as an independent prognostic factor in patients with advanced non-small cell lung cancer treated with first-line therapy. <i>Oncotarget</i> , 2017, 8, 23871-23879.	0.8	36
11	Long-term responders to anti-HER2 therapies: A case report and review of the literature. <i>Molecular and Clinical Oncology</i> , 2017, 8, 147-152.	0.4	7
12	Risk of Hyponatraemia in Cancer Patients Treated with Targeted Therapies: A Systematic Review and Meta-Analysis of Clinical Trials. <i>PLoS ONE</i> , 2016, 11, e0152079.	1.1	38
13	Speckle-tracking global longitudinal strain as an early predictor of cardiotoxicity in breast carcinoma. <i>Supportive Care in Cancer</i> , 2016, 24, 3139-45.	1.0	19
14	Three drugs vs two drugs first-line chemotherapy regimen in advanced gastric cancer patients: a retrospective analysis. <i>SpringerPlus</i> , 2015, 4, 743.	1.2	10
15	Risk of pruritus in cancer patients treated with biological therapies: A systematic review and meta-analysis of clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 206-219.	2.0	22
16	Chromium Exposure and Germinal Embryonal Carcinoma: First Two Cases and Review of the Literature. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 2015, 78, 1-6.	1.1	17
17	Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients. <i>BMC Cancer</i> , 2015, 15, 195.	1.1	101
18	Paclitaxel and Bevacizumab in First Line-Treatment Patients with HER-2 Negative Advanced Breast Cancer: Who could Benefit?. <i>Chemotherapy</i> , 2014, 03, .	0.0	0

#	ARTICLE	IF	CITATIONS
19	Metastatic breast cancer mimicking a hilar cholangiocarcinoma: case report and review of the literature. <i>World Journal of Surgical Oncology</i> , 2014, 12, 384.	0.8	16
20	Androgen Receptor Expression in Early Triple-Negative Breast Cancer: Clinical Significance and Prognostic Associations. <i>Cancers</i> , 2014, 6, 1351-1362.	1.7	61
21	Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer. <i>OncoTargets and Therapy</i> , 2013, 6, 563.	1.0	22
22	Clinical Evidence for Three Distinct Gastric Cancer Subtypes: Time for a New Approach. <i>PLoS ONE</i> , 2013, 8, e78544.	1.1	14
23	Prognostic factors in early-stage triple-negative breast cancer: lessons and limits from clinical practice. <i>Anticancer Research</i> , 2013, 33, 2737-42.	0.5	24
24	Phase II study of pharmacogenetic-tailored therapy in elderly colorectal cancer patients. <i>Digestive and Liver Disease</i> , 2012, 44, 74-79.	0.4	3
25	Role of Vascular Endothelial Growth Factor (VEGF) and VEGF-R Genotyping in Guiding the Metastatic Process in pT4a Resected Gastric Cancer Patients. <i>PLoS ONE</i> , 2012, 7, e38192.	1.1	15
26	5-fluorouracil pharmacogenomics: still rocking after all these years?. <i>Pharmacogenomics</i> , 2011, 12, 251-265.	0.6	54
27	Second-line chemotherapy with irinotecan, 5-fluorouracil and leucovorin (FOLFIRI) in relapsed or metastatic gastric cancer: lessons from clinical practice. <i>Tumori</i> , 2011, 97, 275-9.	0.6	1
28	Novel Perspectives for the Treatment of Gastric Cancer: From a Global Approach to a Personalized Strategy. <i>Current Oncology Reports</i> , 2010, 12, 175-185.	1.8	13
29	Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer. <i>Core Evidence</i> , 2010, 5, 61.	4.7	11
30	Locally advanced rectal cancer: from molecular profiling to clinical practice. A literature review: Part 2. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 2467-2478.	0.9	6
31	Toward molecularly selected chemotherapy for advanced gastric cancer: State of the art and future perspectives. <i>Cancer Treatment Reviews</i> , 2009, 35, 451-462.	3.4	24
32	Multidisciplinary treatment of locally advanced rectal cancer: a literature review. Part 1. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 2245-2258.	0.9	12